Kiera L. Delgaty

Evaluator - Animate Products of Biotechnology (Micro-organisms & Genetically Modified Higher Organisms)

Current research and/or projects

Evaluating risks to Canadians, their health and their environment posed by toxic and other harmful substances in support of the Chemicals Management Plan and Risk Assessment program

  • Assessment of animate products of biotechnology under Part 6 of CEPA 1999 and The New Substances Notification Regulations (Organisms) & development of control measures; Review of environmental assessments of Food and Drug Act substances notified under CEPA 1999 and conducted by the Environmental Assessment Unit, Health Canada.
  • Screening Assessment of living organisms on the DSL as required by Section 74(b) of CEPA 1999
  • Development of Guidelines and SOP's ; Participation in the Interdepartmental Working Group for Microorganisms and in the CEPA Biotechnology Working Group
  • Review of Scientific Research Projects funded under the Canadian Regulatory System for Biotechnology (CRSB) to address data gaps and testing and method development.
  • Provide expert scientific advice and out-reach to Environment Canada colleagues and external stakeholders.

Professional activities / interests

EC Evaluator Representative, Interdepartmental Working Group – Micro-organisms

Education and awards

M.Sc., Microbiology & Immunology (infectious disease, mechanisms of pathogenesis, molecular biology), University of Ottawa, Ottawa, Ontario

B.Sc. Honours, Biology/Chemistry, Trent University, Peterborough, Ontario

Key publications

Shahsavarani, A., K. L. Delgaty, K. Ali and J. Beardall. 2007. The Canadian Environmental Protection Act, 1999 and the regulation of animate products of biotechnology: Organisms other than micro-organisms. Transgenic Animal Research Conference VI, Lake Tahoe, California. Transgenic Research 16(6):835-837.

Ouakfaoui, S.E, L.-A. Tsan, T. Paré and K. Delgaty. 2005. Environmental risk assessment of Bacillus thuringiensis strain ATCC 13367 under the Canadian Environmental Protection Act 1999 (CEPA 1999). 6th Pacific Rim Conference on the Biotechnology of Bacillus thuringiensis and Its Environmental Impact, Vancouver, BC.

Desjardins, M., K.L. Delgaty, K. Ramotar, C. Seetaram and B. Toye. 2004. Prevalence and mechanisms of erythromycin resistance in Group A and Group B Streptococcus: Implications for reporting and susceptibility results. Journal of Clinical Microbiology, 42 (12): 5620-5623.

Delgaty, K.L. 2000. Identification and molecular characterisation of a putative gene for cell detaching factor from Trichomonas vaginalis. Thesis.

Hayward-McClelland, S., K.L. Delgaty and G.E. Garber. 1999. Animal Models of Trichomonas vaginalis infection: The Intravaginal Mouse Model, Chapter 100. in Zak, O., and Sande, M. 1999. Animal Models of Infection. Academic Press, London. pp 839-850.

Petrin, D.P., K.L. Delgaty, R. Bhatt and G.E. Garber 1998. Clinical and microbiological aspects of Trichomonas vaginalis. Clinical Microbiology Reviews 11(2):300-317.

Hu, Y-W. et al. 2001. Evaluation, comparison, and application of a novel assay, semi-automated primer specific and mispair extension analysis (S-PSMEA), direct DNA sequencing, and population based sequencing for detection of low levels of HIV-1 drug resistance mutants. Canadian Association of HIV Research: Tenth Annual Canadian Conference on HIV/AIDS Research. Toronto, 2001. Journal of the Association of Medical Microbiology and Infectious Disease Canada. May/June 2001. Vol. 12 Supplement SB.

Cudmore, S.L., K.L. Delgaty, S.F. Hayward-McClelland, D.P. Petrin and G.E. Garber. 2004. Treatment of Infections Caused by Metronidazole-Resistant Trichomonas vaginalis. Clinical Microbiology Reviews, 17( 4): 783-793.


Member, American Society for Microbiology

Member, Canadian Society of Microbiologists